Sec. 8. If:
(1) the federal government indicates that the federal government will withdraw all federal funds from a health care facility for allowing amygdalin (laetrile) to be used within the facility; and
(2) providing or allowing use of amygdalin (laetrile) within the facility would jeopardize the receipt of:
(A) federal funds for reimbursement for Medicare or Medicaid for all persons within the facility; or
(B) construction funds provided by the federal government under the Hill-Burton Hospital Construction Program (42 U.S.C. 291 et seq.) or under Title XVI of the Public Health Services Act (42 U.S.C. 300q-300t);
the hospital or other health care facility may prohibit the use of amygdalin (laetrile) within the hospital or facility.
[Pre-1993 Recodification Citation: 16-8-8-7(b).]
As added by P.L.2-1993, SEC.25.
Structure Indiana Code
Article 42. Regulation of Food, Drugs, and Cosmetics
Chapter 23. Drugs: Use of Amygdalin (Laetrile)
16-42-23-1. Health Care Facilities; Restrictions on Use
16-42-23-2. Disciplinary Action Against Attending Physician
16-42-23-3. Prescription or Administration Permitted With Written Informed Request
16-42-23-4. Construction of Chapter
16-42-23-5. Written Informed Request Form
16-42-23-6. Regulation of Use, Sale, Prescription, Manufacture, or Distribution Within State
16-42-23-7. Required Manufacture, Sale, Distribution, or Prescription